Latest News & FeaturesMore News
  • Biden Names 20 National Academies Members to PCAST
    Wed, September 22, 2021
    President Biden announced the members of the President’s Council of Advisors on Science and Technology (PCAST), 20 of whom are also members of NAS, NAE, and NAM. PCAST is the sole body of external advisers that makes science, technology, and innovation policy recommendations to the president and ...
All Events
Upcoming Events
Members
President's Corner
NAE Perspectives
NAE Perspectives offer practitioners, scholars, and policy leaders a platform to comment on developments and issues relating to engineering.
  • image for Evolutionary Medicine Needs Engineering Expertise
    Engineering has made vast contributions to health and medicine, from designing water and sewer systems that have saved millions of lives to optimizing healthcare delivery systems and creating ever more sophisticated medical devices. New applications of evolutionary biology to medicine are now giving rise to new opportunities for engineering to enhance understanding of disease. Projects that bring engineering expertise to bear on the questions addressed by evolutionary medicine promise major advances.
  • image for Driverless Motor Vehicles: Not Yet Ready for Prime Time
    According to safety experts, more than 90% of motor vehicle crashes involve driver error,[1] and many believe that replacing drivers with automation could significantly reduce the number of crashes. Well-considered automation could compensate for human susceptibilities such as fatigue, distraction, and impairment that contribute to crashes, and thus greatly reduce the loss of nearly 40,000 lives every year on US streets and highways. Read more in a Perspective by Christopher A. Hart, founder of Hart Solutions LLC and former chair of the National Transportation Safety Board.
  • image for Protecting Human Health through Biotechnology Breakthroughs and Platforms
    Moderna spent a decade combining chemical, systems, and bio engineering advances to create the mRNA platform for its COVID-19 vaccine. On November 15, 2020, after 4 months in large-scale Phase 3 clinical testing, Moderna received resounding proof that its new class of medicines based on messenger RNA encased in lipid nanoparticles could be safely deployed as a highly effective vaccine to combat the covid-19 pandemic. Read the latest NAE Perspectives as chairman Noubar Afeyan explores lessons learned to stop other health threats.
Stay in touch with NAE